| Literature DB >> 34263166 |
Appiah-Korang Labi1, Noah Obeng-Nkrumah2, Nicholas T K D Dayie1, Beverly Egyir3, Eric Sampane-Donkor1, Mercy Jemima Newman1, Japheth Awuletey Opintan1.
Abstract
BACKGROUND: Antimicrobial resistance (AMR) is a public health crisis of global proportions. Data is required to understand the local drivers of antimicrobial resistance and support decision-making processes including implementation of appropriate antimicrobial stewardship strategies.Entities:
Year: 2021 PMID: 34263166 PMCID: PMC8275021 DOI: 10.1093/jacamr/dlab087
Source DB: PubMed Journal: JAC Antimicrob Resist ISSN: 2632-1823
Figure 1.Prevalence of antibiotic use across study hospitals categorized as primary, secondary and tertiary. The diameter of the prevalence circle is proportional to the antibiotic use burden. Please note that St. Martins De-Porres Hospital is referred to as Eikwe District Hospital.
Summary of antimicrobial prescriptions for 2897 patients on admission
| Prescriptions | Number of patients (%) | Number of prescriptions (%) |
|---|---|---|
| Anti-infective agents | 1591 (54.9) | 2875 (100) |
| Antibiotics only | 1439 (49.6) | 2399 (83.4) |
| Antibiotics with ‘other antimicrobials’ | 123 (4.2) | 221 (7.7) |
| At least one antibiotic drug | 1562 (53.9) | 2620 (91.1) |
| Only ‘other antimicrobials’ | 29 (1.0) | 34 (1.2) |
| At least one ‘other antimicrobial’ drug | 152 (5.2) | 255 (8.9) |
| Anti-TB | 36 (1.2) | 85 (2.9) |
| Antimalarials | 66 (2.2) | 70 (2.4) |
| Antivirals | 34 (1.2) | 67 (2.3) |
| Antifungals | 30 (1.0) | 33 (1.1) |
Prescribed antibiotics with or without ‘other antimicrobial drugs’.
Given ‘other antimicrobials’ without any antibiotic prescription.
Patients prescribed ‘other antimicrobials’ with or without antibiotics.
The numbers of patients on anti-TB, antimalarials, antivirals, antifungals do not add up to 152 due to overlap in prescriptions.
Anti-TB, antituberculosis drugs.
Prevalence of patients on antibiotics (ABX)
| Description by hospital type | ADM | No. of patients on ABX (%) | Adults | Neonates | Paediatrics | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical | Surgical | ICU | Medical | Intensive care | Medical | Surgical | ICU | |||||||||||
| ADM | ABX (%) | ADM | ABX (%) | ADM | ABX (%) | ADM | ABX (%) | ADM | ABX (%) | ADM | ABX (%) | ADM | ABX (%) | ADM | ABX (%) | |||
| Primary | ||||||||||||||||||
| Hospital 1 | 122 | 79 (64.8) | 45 | 30 (66.7) | 51 | 29 (56.9) | 0 | 0 | 3 | 3 (100.0) | 20 | 15 (75.0) | 3 | 2 (66.7) | 0 | |||
| Secondary | ||||||||||||||||||
| Hospital 2 | 150 | 86 (57.4) | 60 | 26 (43.3) | 55 | 43 (78.2) | 0 | 0 | 0 | 13 | 7 (53.8) | 0 | 22 | 10 (45.5) | ||||
| Hospital 3 | 318 | 159 (50.0) | 127 | 72 (56.7) | 123 | 44 (35.8) | 1 | 1 (100.0) | 0 | 30 | 15 (50.0) | 37 | 27 (73.0) | 0 | 0 | |||
|
| 468 | 245 (52.4) | 187 | 98 (52.4) | 178 | 87 (48.9) | 1 | 1 (100.0) | 0 | 0 | 30 | 15 (50.0) | 50 | 34 (68.0) | 0 | 0 | 22 | 10 (45.5) |
| Tertiary | ||||||||||||||||||
| Hospital 4 | 629 | 367 (58.4) | 158 | 84 (53.2) | 273 | 145 (53.1) | 16 | 13 (81.3) | 65 | 34 (52.3) | 21 | 14 (66.7) | 69 | 60 (87.0) | 25 | 16 (64.0) | 2 | 1 (50.0) |
| Hospital 5 | 988 | 515 (52.1) | 459 | 238 (51.9) | 324 | 158 (48.8) | 7 | 7 (100.0) | 0 | 86 | 41 (47.7) | 80 | 55 (68.8) | 32 | 16 (50.0) | 0 | ||
| Hospital 6 | 140 | 93 (66.4) | 54 | 28 (51.9) | 58 | 41 (70.7) | 2 | 2 (100.0) | 5 | 5 (100.0) | 5 | 4 (80.0) | 16 | 13 (81.3) | 0 | 0 | ||
| Hospital 7 | 550 | 263 (47.8) | 122 | 48 (39.3) | 333 | 150 (45.0) | 2 | 2 (100.0) | 52 | 38 (73.1) | 0 | 41 | 25 (61.0) | 0 | 0 | |||
|
| 2307 | 1238 (53.7) | 793 | 398 (50.2) | 988 | 494 (50.0) | 27 | 24 (88.9) | 122 | 77 (63.1) | 112 | 59 (52.7) | 206 | 153 (74.3) | 57 | 32 (56.1) | 2 | 1 (50.0) |
| Overall | 2897 | 1562 (53.9) | 1025 | 526 (51.3) | 1217 | 610 (50.1) | 28 | 25 (89.3) | 122 | 77 (63.1) | 145 | 77 (53.1) | 276 | 202 (73.2) | 60 | 34 (56.7) | 24 | 11 (45.8) |
ADM, number of patients on admission.
Figure 2.(a) Drug utilization at 100% (DU100%) by ATC level 5 and (b) the indications for use. Abbreviations: CAI, community-acquired infections, HAI, healthcare-associated infections, MP, medical prophylaxis, SP, Surgical prophylaxis.
Top five antibiotics (ATC level 5) prescribed for patients by type of infection (September to December 2019)
| Reasons for antibiotic use | Top 5 antibiotics used (ATC level 5) among all patients | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | First | Second | Third | Fourth | Fifth | ||||||||||||
| no. | (%) | Antibiotic | no. | (%) | Antibiotic | no. | (%) | Antibiotic | no. | (%) | Antibiotic | no. | (%) | Antibiotic | no. | (%) | |
| Infections | 1367 | (52.2) | |||||||||||||||
| Skin and soft tissue | 289 | (11.0) | CLI | 80 | (27.7) | MTZ | 51 | (17.6) | CIP | 38 | (13.1) | CXM | 37 | (12.8) | CTO | 20 | (6.9) |
| Bone/joint | 48 | (1.8) | CLI | 17 | (35.4) | CXM | 9 | (18.8) | CIP | 7 | (14.6) | AMC | 5 | (10.4) | FLX | 2 | (4.2) |
| Lower UTI | 90 | (3.4) | CXM | 52 | (57.8) | CIP | 12 | (13.3) | CTO | 9 | (10.0) | MTZ | 4 | (4.4) | AMX | 3 | (3.3) |
| Upper UTI | 40 | (1.5) | CXM | 12 | (30.0) | CTO | 5 | (12.5) | CIP | 4 | (10.0) | GEN, MEM | 3 | (7.5) | MTZ, NIT, CXM | 2 | (5.0) |
| Pneumonia or LRTI | 325 | (12.4) | CTO | 64 | (19.7) | AZM | 62 | (19.1) | AMC | 45 | (13.8) | MTZ | 28 | (8.6) | CXM | 26 | (8.0) |
| Upper RTI | 6 | (0.2) | CTO | 2 | (33.3) | CXM, AMC, GEM, AMX, CTO | 1 | (16.7) | |||||||||
| Obs/Gynae | 60 | (2.3) | MTZ | 18 | (30.0) | AMC | 9 | (15.0) | CLI | 8 | (13.3) | GEN | 6 | (10.0) | CTO | 5 | (8.3) |
| GU infections | 6 | (0.2) | PEN, CXM, DOX GEN, MTZ | 1 | (16.7) | (0.0) | (0.0) | ||||||||||
| Sepsis | 223 | (8.5) | CTO | 35 | (15.7) | GEN | 25 | (11.2) | CLX | 24 | (10.8) | CTX | 20 | (9.0) | AMK | 16 | (7.2) |
| PUO | 15 | (0.6) | CTO, CIP | 4 | (26.7) | GEN | 2 | (13.3) | AZM, CXM, AMC, CLI, LVX | 1 | (6.7) | (0.0) | (0.0) | ||||
| CNS | 85 | (3.2) | CTO | 28 | (32.9) | MTZ | 10 | (11.8) | COT | 7 | (8.2) | CXM, CIP | 5 | (5.9) | COT, GEN | 4 | (4.7) |
| Intra-abdominal | 52 | (2.0) | MTZ | 21 | (40.4) | CIP | 9 | (17.3) | CTO | 8 | (15.4) | CXM | 4 | (7.7) | AMC | 3 | (5.8) |
| GI | 101 | (3.9) | MTZ | 44 | (43.6) | CIP | 22 | (21.8) | CTO | 8 | (7.9) | AMX | 7 | (6.9) | CLR | 4 | (4.0) |
| ENT | 17 | (0.6) | CTO, AMC, MTZ | 3 | (17.6) | PEN, AMX, GEN | 2 | (11.8) | CLI, AMK | 1 | (5.9) | ||||||
| CVS | 3 | (0.1) | PEN, AMX, CTO | 1 | (33.3) | ||||||||||||
| Other infections | 7 | (0.3) | AMX, CTO, MTZ, ERY, FLX, GEN, MTZ | 1 | (14.3) | ||||||||||||
| Prophylaxis | 893 | (34.1) | MTZ | 276 | (30.9) | AMC | 121 | (13.5) | CXM | 116 | (13.0) | AMX | 73 | (8.2) | CTO | 57 | (6.4) |
| Medical | 209 | (8.0) | MTZ | 29 | (13.9) | AMC, CXM | 23 | (11.0) | GEN | 18 | (8.6) | CIP | 16 | (7.7) | AMK | 15 | (7.2) |
| Surgical | 684 | (26.1) | MTZ | 247 | (36.1) | AMC | 113 | (16.5) | CXM | 93 | (13.6) | AMX | 65 | (9.5) | CTO | 60 | (8.8) |
| Unknown reasons | 360 | (13.7) | MTZ | 65 | (18.1) | CXM, CTO | 48 | (13.3) | GEN | 34 | (9.4) | AMP | 28 | (7.8) | CIP | 27 | (7.5) |
| All prescriptions | 2620 | MTZ | 541 | (20.6) | CXM | 338 | (12.9) | CTO | 310 | (11.8) | AMC | 231 | (8.8) | CIP | 204 | (7.8) | |
ATC, Anatomic therapeutic classification; UTI, urinary tract infections; LRTI, lower respiratory tract infections; Obs/Gynae obstetrics and gynaecological infections; GU, genitourinary infections in men; PUO, pyrexia of unknown origin; GI, gastrointestinal tract; ENT, ear, nose and throat; CVS, cardiovascular system; CLI, clindamycin, CXM, cefuroxime, CTO, ceftriaxone; MTZ, metronidazole; PEN, benzylpenicillin; DOX, doxycycline; GEN, gentamicin; CIP, ciprofloxacin; AMC, amoxicillin/clavulanic acid; AMX, amoxicillin; ERY, erythromycin; FLX, flucloxacillin; GEM, gemifloxacin; AZM, azithromycin; LVX, levofloxacin; COT, cotrimoxazole; AMK, amikacin; CTX, cefotaxime; AMP, ampicillin; NIT, nitrofurantoin; CLR, clarithromycin.
Figure 3.Summary of (a) prophylactic antibiotic use, (b) antibiotics prescribed for surgical prophylaxis and (c) the duration of prescription antibiotics prescribed for medical prophylaxis and the indications for prescription.
Overview of quality of prescription for antimicrobial drugs
| Patients | Anti-infective prescriptions | Antibiotic prescriptions, | Antibiotic use guidelines available | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number | Based on biomarker | Reason in notes | Stop/ review date | Targeted treatment | ||||||
| CRP | PCT | WBC | All | |||||||
| Hospital 1 ( | 295 | 273 (92.5) | 0 | 0 | 4 (2.5) | 4 (2.5) | 165 (60.4) | 49 (17.9) | 1 (0.4) | none |
| Hospital 2 ( | 154 | 140 (90.1) | 0 | 0 | 24 (15.4) | 24 (15.4) | 47 (33.6) | 79 (54.6) | 0 | none |
| Hospital 3 ( | 148 | 137 (92.5) | 0 | 0 | 0 | 0 | 82 (59.9) | 103 (75.2) | 0 | none |
| Hospital 4 ( | 193 | 161 (83.4) | 0 | 0 | 13 (82.9) | 13 (82.9) | 108 (67.1) | 113 (70.2) | 3 (1.9) | none |
| Hospital 5 ( | 700 | 609 (87.0) | 0 | 0 | 37 (23.7) | 37 (23.7) | 314 (51.6) | 406 (66.7) | 10 (1.6) | none |
| Hospital 6 ( | 967 | 890 (92.3) | 7 (0.8) | 6 (0.7) | 34 (21.8) | 46 (27.2) | 388 (43.6) | 201 (22.6) | 31 (3.5) | none |
| Hospital 7 ( | 418 | 410 (98.1) | 0 | 0 | 44 (28.2) | 44 (26.0) | 158 (38.5) | 275 (67.1) | 8 (2.0) | none |
| Total ( | 2875 | 2620 (91.1) | 7 (0.5) | 6 (0.4) | 156 (11.4) | 169 (12.4) | 1262 (48.2) | 1226 (46.7) | 53 (3.9) | – |
Antibiotic prescriptions for systemic therapeutic use only (i.e., healthcare-associated or community-acquired infection, n = 1367); CRP, C-reactive protein; PCT, procalcitonin; WBC, white blood cells.